Skip to main content

DC-based immunotherapy to treat Malignant Mesothelioma

Objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Call for proposal

H2020-PHC-2014-2015

See other projects for this call

Sub call

H2020-PHC-2015-two-stage

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Net EU contribution
€ 2 375 146,94
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands

See on map

Region
West-Nederland Zuid-Holland Groot-Rijnmond
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (8)

UNIVERSITA POLITECNICA DELLE MARCHE
Italy
Net EU contribution
€ 372 021,48
Address
Piazza Roma 22
60121 Ancona

See on map

Region
Centro (IT) Marche Ancona
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

Azienda Ospedaliero Univesitaria Ospedali Riuniti Umberto I- G.M. Lancisi- G. Salesi
Italy
Net EU contribution
€ 297 431,25
Address
Via Conca 71
60126 Ancona

See on map

Region
Centro (IT) Marche Ancona
Activity type
Research Organisations
Non-EU contribution
€ 0,00
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
Net EU contribution
€ 669 451,91
Address
Plesmanlaan 121
1066 CX Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Research Organisations
Non-EU contribution
€ 0,00
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
Net EU contribution
€ 668 874,95
Address
Drie Eikenstraat 655
2650 Edegem

See on map

Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Research Organisations
Non-EU contribution
€ 0,00
UNIVERSITY OF LEICESTER
United Kingdom
Net EU contribution
€ 669 215,63
Address
University Road
LE1 7RH Leicester

See on map

Region
East Midlands (England) Leicestershire, Rutland and Northamptonshire Leicester
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
Net EU contribution
€ 659 822,84
Address
Avenue Oscar Lambret 2
59037 Lille

See on map

Region
Hauts-de-France Nord-Pas de Calais Nord
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
EUROPEAN CANCER PATIENT COALITION
Belgium
Net EU contribution
€ 23 000,00
Address
Rue Montoyer 40
1000 Bruxelles

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Other
Non-EU contribution
€ 0,00
AMPHERA BV
Netherlands
Net EU contribution
€ 48 000,00
Address
Onderwijsboulevard 225
5223 DE Den Bosch

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Noord-Brabant Noordoost-Noord-Brabant
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00